세계의 잔류 DNA 검사 시장 : 제공 제품별, 검사 유형별, 기술별, 용도별, 최종사용자별, 지역별 - 예측(-2030년)

The residual DNA testing market is projected to reach USD 0.37 billion by 2030 from USD 0.28 billion in 2025, at a CAGR of 6.0% during the forecast period. The expansion of this market is fueled by multiple factors, including the increasing frequency of approvals for biologics and biosimilars, as well as the implementation of rigorous regulatory frameworks governing the manufacture of biopharmaceutical products. Additionally, advancements in technologies related to residual DNA testing are anticipated to further bolster market growth throughout the forecast period.

By technology, the PCR segment accounted for the largest share of the residual DNA testing market in 2024.

By technology, the market is segmented into PCR, threshold Assays, DNA probe hybridization, and other technologies. In 2024, the Polymerase Chain Reaction (PCR) segment commanded the largest share of the market, reflecting its pivotal role in molecular diagnostics. This substantial market share can be primarily attributed to the high sensitivity and specificity offered by PCR, which enables the precise detection of even minute quantities of residual DNA. As a result, PCR effectively minimizes the risk of false positives, a critical factor in ensuring accurate test outcomes. Moreover, the versatility of the PCR technology plays a significant role in its widespread adoption. It can be easily adapted for various test types, making it applicable across a broad spectrum of biopharmaceutical applications. This adaptability, combined with its scalability, allows PCR to be employed in everything from small-scale research studies to large-scale clinical testing, catering to the evolving needs of the biopharmaceutical industry. With its exceptional performance characteristics and flexible applications, the PCR segment continues to be a cornerstone of advancements in molecular biology and diagnostics.

In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the residual DNA testing services market.

The residual DNA testing services market is categorized into two primary segments: pharmaceutical & biotechnology companies and academic & research institutes. As of 2024, the pharmaceutical & biotechnology companies segment holds the largest share of the market. This substantial growth can be attributed to the increasing emphasis on the development of biologics, which are innovative therapies aimed at treating a variety of diseases, including cancers, autoimmune disorders, and genetic conditions. As the industry evolves, pharmaceutical and biotechnology firms are required to adhere to stringent regulatory standards, which mandate the provision of comprehensive data concerning the entire manufacturing process. This includes the rigorous testing and validation of biological products to ensure their safety and efficacy. Consequently, the necessity for thorough quality inspections and regulatory approvals becomes paramount, driving the demand for residual DNA testing services. These services play a critical role in identifying and quantifying residual DNA left in biologics, ensuring that products meet safety guidelines and are free from contaminants that could pose risks to patients. Moreover, as companies invest in advanced biotechnological research and development, the demand for reliable and accurate testing methods continues to rise. This trend further augments the market for residual DNA testing services, highlighting its essential role in the pharmaceutical landscape. As the sector strives for innovation and compliance, the importance of these testing services will likely increase, underscoring their value in advancing medical science and patient safety.

In 2024, North America accounted for the largest share of the residual DNA testing market.

In 2024, North America emerged as the dominant force in the market, largely due to the strong presence of key industry leaders and a notable expansion in research initiatives aimed at innovating and developing biologics. This growth can be attributed to a significant increase in research and development investments within the life sciences sector, which, in turn, has escalated the demand for residual DNA testing products and services. Additionally, the region benefits from a concentration of numerous global entities, including pharmaceutical companies, biotech firms, and academic institutions, which collectively enhance its leadership position in the market. This collaborative environment fosters innovation and accelerates advancements in biologics, further solidifying North America's role as a pivotal hub for life sciences R&D.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: CXOs and Directors- 30%, Managers- 45%, and Executives- 25%
• By Region: North America -35%, Europe - 25%, Asia Pacific -15%, Latin America -10%, Middle East- 10%, and Africa- 5%

List of companies profiled in the report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• Charles River Laboratories (US)
• Bio-Rad Laboratories (US)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd (Switerland)
• Maravai LifeSciences (US)
• FUJIFILM Corporation (Japan)
• SGS Societe Generale de Surveillance SA (Switzerland)
• Jiangsu Hillgene Biopharma Co.,Ltd (China)
• Revvity (US)
• Intertek Group plc (UK)
• WuXi AppTec (China)
• Sartorius AG (Germany)
• Lonza (Switzerland)

Research Coverage:

This research report categorizes residual DNA testing market by offering (products and services), technology (PCR, threshold assay, DNA probe hybridization, and other technologies), test type (final product release testing, bulk lot release testing, and final product release testing), application (monoclonal antibodies, cell & gene therapy, vaccines, and other applications), end user for products (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), end user for services (pharmaceutical & biotechnology companies and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The report offers an in-depth examination of the critical elements shaping the residual DNA testing market, including key drivers, constraints, challenges, and emerging opportunities. It presents a comprehensive analysis of leading industry players, detailing their business models, product and service offerings, strategic initiatives, new launches, acquisitions, and recent advancements pertinent to the residual DNA testing sector. Additionally, this report includes a competitive landscape assessment of emerging startups within the residual DNA testing ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the residual DNA testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following:

• Analysis of key drivers (Increase in biologics and biosimilars approvals, stringent regulatory compliance requirements, technological advancements in DNA quantification and detection, increasing cell culture contamination risks, rising investments in R&D spending), restraints (high cost of advanced testing techniques, lack of standardization across testing protocols), opportunities (application in novel modalities such as mRNA vaccines, cell therapies, and gene therapies, growth opportunities in emerging markets, integration with continuous and accelerated bioprocessing, rising outsourcing to CROs and CDMOs), and challenges (complexity in sample preparation and assay validation) are influencing the growth of the residual DNA testing market.
• Product Development/Innovation: Detailed insights on newly launched products of the residual DNA testing market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the residual DNA testing market across varied regions.
• Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the residual DNA testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Eurofins Scientific (Luxembourg), among others, offering products and services for the residual DNA testing market. Other companies in this market include TransGen Biotech Co., Ltd. (China), Vazyme International LLC (China), and EagleBio (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources of secondary data
    • 2.1.1.2 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (bottom-up approach)
    • 2.2.1.2 Insights of primary experts
  • 2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 RESIDUAL DNA TESTING MARKET OVERVIEW
• 4.2 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE AND COUNTRY
• 4.3 RESIDUAL DNA TESTING PRODUCTS MARKET SHARE, BY END USER, 2024
• 4.4 RESIDUAL DNA TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing number of biologics and biosimilar approvals
    • 5.2.1.2 Stringent regulatory compliance requirements
    • 5.2.1.3 Technological advancements in DNA quantification and detection
    • 5.2.1.4 Increasing risk of cell culture contamination
    • 5.2.1.5 Rising biopharmaceutical R&D investments
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High costs of advanced testing techniques
    • 5.2.2.2 Lack of standardization across testing protocols
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising number of applications in novel modalities
    • 5.2.3.2 High growth opportunities in emerging markets
    • 5.2.3.3 Integration with continuous and accelerated bioprocessing
    • 5.2.3.4 Rising outsourcing to CROs and CDMOs
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Complexity in sample preparation and assay validation
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS, BY REGION, 2022-2024
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 ECOSYSTEM ANALYSIS
  • 5.6.1 ROLE IN ECOSYSTEM
• 5.7 INVESTMENT & FUNDING SCENARIO
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 Quantitative PCR (qPCR)
    • 5.8.1.2 Droplet digital PCR (ddPCR)
    • 5.8.1.3 Next-generation sequencing (NGS)
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Automated magnetic bead-based DNA extraction
    • 5.8.2.2 Capillary electrophoresis
    • 5.8.2.3 Nanopore sequencing
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 High-performance liquid chromatography (HPLC)
    • 5.8.3.2 Electron microscopy
    • 5.8.3.3 Mass spectrometry
• 5.9 PATENT ANALYSIS
  • 5.9.1 LIST OF KEY PATENTS
• 5.10 KEY CONFERENCES & EVENTS, 2025-2026
• 5.11 REGULATORY ANALYSIS
  • 5.11.1 REGULATORY FRAMEWORK
    • 5.11.1.1 North America
      • 5.11.1.1.1 US
      • 5.11.1.1.2 Canada
    • 5.11.1.2 Europe
      • 5.11.1.2.1 UK
    • 5.11.1.3 Asia Pacific
      • 5.11.1.3.1 China
      • 5.11.1.3.2 Japan
      • 5.11.1.3.3 India
  • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.12 PORTER'S FIVE FORCES ANALYSIS
  • 5.12.1 BARGAINING POWER OF SUPPLIERS
  • 5.12.2 BARGAINING POWER OF BUYERS
  • 5.12.3 THREAT OF NEW ENTRANTS
  • 5.12.4 THREAT OF SUBSTITUTES
  • 5.12.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.13.2 KEY BUYING CRITERIA, BY END USER
• 5.14 IMPACT OF AI/GEN AI ON RESIDUAL DNA TESTING MARKET
  • 5.14.1 MARKET POTENTIAL OF AI IN RESIDUAL DNA TESTING
  • 5.14.2 AI USE CASES
  • 5.14.3 KEY COMPANIES IMPLEMENTING AI/GEN AI
  • 5.14.4 FUTURE OF AI/GEN AI IN RESIDUAL DNA TESTING MARKET
• 5.15 TRADE DATA ANALYSIS
  • 5.15.1 IMPORT DATA FOR HS CODE 9027, 2020-2024
  • 5.15.2 EXPORT DATA FOR HS CODE 9027, 2020-2024
• 5.16 IMPACT OF 2025 US TARIFF ON RESIDUAL DNA TESTING MARKET
  • 5.16.1 KEY TARIFF RATES
  • 5.16.2 PRICE IMPACT ANALYSIS
  • 5.16.3 IMPACT ON COUNTRIES/REGIONS
    • 5.16.3.1 North America
      • 5.16.3.1.1 US
    • 5.16.3.2 Europe
    • 5.16.3.3 Asia Pacific
    • 5.16.3.4 Rest of the World
  • 5.16.4 IMPACT ON END-USE INDUSTRIES
    • 5.16.4.1 Pharmaceutical & biotechnology companies
    • 5.16.4.2 CROs & CDMOs
    • 5.16.4.3 Academic & research institutes

6 RESIDUAL DNA TESTING MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 PRODUCTS
  • 6.2.1 CONSUMABLES
    • 6.2.1.1 Increasing focus on development of biologics and biosimilars to propel segment growth
  • 6.2.2 INSTRUMENTS & SOFTWARE
    • 6.2.2.1 Continuous advancement in analytical technologies to fuel segment growth
• 6.3 SERVICES
  • 6.3.1 STRINGENT REGULATORY STANDARDS TO PROMOTE MARKET GROWTH

7 RESIDUAL DNA TESTING MARKET, BY TEST TYPE

• 7.1 INTRODUCTION
• 7.2 FINAL PRODUCT RELEASE TESTING
  • 7.2.1 FAVORABLE REGULATORY MANDATES AND BIOLOGICS INNOVATION TO FUEL MARKET GROWTH
• 7.3 BULK LOT RELEASE TESTING
  • 7.3.1 INCREASING BIOLOGIC COMPLEXITY TO FUEL MARKET GROWTH
• 7.4 RAW MATERIAL TESTING
  • 7.4.1 ENHANCED FOCUS ON PRODUCT SAFETY AND REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH

8 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY

• 8.1 INTRODUCTION
• 8.2 POLYMERASE CHAIN REACTION
  • 8.2.1 HIGH THROUGHPUT DETECTION TO SUPPORT SEGMENT DOMINANCE
• 8.3 THRESHOLD ASSAYS
  • 8.3.1 HIGH SPECIFICITY OF DNA DETECTION AT LOW CONCENTRATION TO FUEL MARKET GROWTH
• 8.4 DNA PROBE HYBRIDIZATION
  • 8.4.1 EASY-TO-USE PORTFOLIO TO BOOST ADOPTION OF DNA PROBE HYBRIDIZATION
• 8.5 OTHER TECHNOLOGIES

9 RESIDUAL DNA TESTING MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 MONOCLONAL ANTIBODIES
  • 9.2.1 EXPANSION OF BIOSIMILAR PIPELINE TO AID MARKET GROWTH
• 9.3 CELL & GENE THERAPY
  • 9.3.1 RISING POPULARITY OF VIRAL VECTOR-BASED SYSTEMS AND INCREASING REGULATORY APPROVALS TO AID MARKET GROWTH
• 9.4 VACCINES
  • 9.4.1 PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
• 9.5 OTHER APPLICATIONS

10 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.2.1 HIGH BIOPHARMACEUTICAL R&D SPENDING AND INCREASED REGULATORY PRESSURE TO FUEL MARKET GROWTH
• 10.3 CROS & CDMOS
  • 10.3.1 FOCUS ON BIOLOGICS DEVELOPMENT AND CDMO FACILITY EXPANSION TO BOOST MARKET GROWTH
• 10.4 ACADEMIC & RESEARCH INSTITUTES
  • 10.4.1 SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO DRIVE MARKET GROWTH

11 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 SURGE IN R&D INVESTMENTS IN BIOPHARMACEUTICAL INNOVATION TO PROPEL MARKET GROWTH
• 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.3.1 SSLIMITED IN-HOUSE CAPABILITIES TO DRIVE OUTSOURCING

12 RESIDUAL DNA TESTING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American residual DNA testing market during study period
  • 12.2.3 CANADA
    • 12.2.3.1 Increasing government support for biologics manufacturing and rising research funding to propel market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Increasing investments in biopharma and rising focus on developing manufacturing capabilities to drive market
  • 12.3.3 UK
    • 12.3.3.1 Booming life science industry and growing focus on vaccine development to aid market growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Growing biotechnology sector and rising research funding to drive market
  • 12.3.5 ITALY
    • 12.3.5.1 High R&D investments in life sciences research to augment market growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Increasing number of biotech companies to favor market growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 High R&D expenditure and favorable strategic alliances to propel market growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Favorable government initiatives for drug development to support market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increasing R&D investments and funding for life science research to support market growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Increasing strategic alliances and investments to spur market growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Booming life science sector to fuel market growth
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Substantial R&D investments by pharmaceutical companies to fuel market growth
  • 12.5.3 MEXICO
    • 12.5.3.1 Rising government support for biopharmaceutical production to drive market
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Kingdom of Saudi Arabia
      • 12.6.2.1.1 Increasing R&D investments in pharmaceutical industries to drive market
    • 12.6.2.2 UAE
      • 12.6.2.2.1 Investments in biopharma sector to offer growth opportunities
    • 12.6.2.3 Rest of GCC Countries
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 RISING PREVALENCE OF CHRONIC DISEASES AND INCREASING FUNDING FOR BIOPHARMA SECTOR TO FUEL MARKET GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RESIDUAL DNA TESTING MARKET
• 13.3 REVENUE ANALYSIS, 2020-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Offering footprint
    • 13.5.5.4 Technology footprint
    • 13.5.5.5 Test type footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.6.5.1 Detailed list of key startups/SMEs
    • 13.6.5.2 Competitive benchmarking of Key startups/SMEs
• 13.7 COMPANY VALUATION & FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES
  • 13.9.2 DEALS
  • 13.9.3 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 THERMO FISHER SCIENTIFIC INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Expansions
      • 14.1.1.3.2 Other developments
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 CHARLES RIVER LABORATORIES
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 F. HOFFMANN-LA ROCHE LTD.
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 MERCK KGAA
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches
      • 14.1.4.3.2 Expansions
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses & competitive threats
  • 14.1.5 MARAVAI LIFESCIENCES
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses & competitive threats
  • 14.1.6 EUROFINS SCIENTIFIC
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
  • 14.1.7 BIO-RAD LABORATORIES, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
  • 14.1.8 QIAGEN
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
  • 14.1.9 FUJIFILM CORPORATION
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services offered
  • 14.1.10 SGS SOCIETE GENERALE DE SURVEILLANCE SA.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services offered
  • 14.1.11 HILLGENE BIOPHARMA CO., LTD.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services offered
  • 14.1.12 REVVITY
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches
  • 14.1.13 INTERTEK GROUP PLC
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services offered
  • 14.1.14 SARTORIUS AG
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services offered
  • 14.1.15 LONZA
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services offered
  • 14.1.16 WUXI APPTEC
    • 14.1.16.1 Business overview
    • 14.1.16.2 Products/Services offered
• 14.2 OTHER PLAYERS
  • 14.2.1 TRANSGEN BIOTECH CO., LTD.
  • 14.2.2 EAGLEBIO
  • 14.2.3 YEASEN
  • 14.2.4 ACROBIOSYSTEMS
  • 14.2.5 CREATIVE BIOGENE
  • 14.2.6 MINERVA BIOLABS GMBH
  • 14.2.7 CREATIVE PROTEOMICS
  • 14.2.8 AVANCE BIOSCIENCES
  • 14.2.9 GENERI BIOTECH

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS